7/15/2011 8:20:36 AM
U.S. drug reviewers said a new pill from Bristol-Myers Squibb Co (BMY.N) and AstraZeneca Plc (AZN.L) was effective in treating diabetes, but posed a number of safety risks. The pill, with the chemical name dapagliflozin, could also be less effective if patients had kidney problems, reviewers from the Food and Drug Administration said in documents released on Friday. In clinical trials, the drug has been linked to a higher number of bladder and breast cancer.
comments powered by